Journal of Hematology & Thromboembolic Diseases
Open Access

Sheila Siqueira

Publications

• Research Article
  Clinical Prognostic Models in Diffuse Large B Cell Lymphoma Patients are Still Essential in the Rituximab Era
  Author(s): Costa RO, Neto AH, Siqueira S, Lage LAPC, Paula HM, et al. Costa RO, Neto AH, Siqueira S, Lage LAPC, Paula HM, et al.
  
  Introduction: To evaluate a new enhanced IPI proposal by the National Comprehensive Cancer Network (NCCNIPI) in DLBCL patients, we compared the IPI, R-IPI, and NCCN-IPI in DLBCL patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP). Methods: From June 2008 to January 2012, we retrospectively evaluated 146 DLBCL patients treated with RCHOP- 21 referred for cancer treatment in a single institution in Brazil. Patients' clinical data were assessed to calculate the IPI, R-IPI, and NCCN-IPI. Results: Patients' median age was 58.9 years (range 16-86); 85 (57.8%) were female. According to IPI, risk categories were low (n=41, 28.1%), low-intermediate (n=43, 29.5%), high-intermediate (n=37, 25.3%), and high (n=25, 17.1%). Using R-IPI, risk categories were very go.. View More»
  DOI: 10.4172/2329-8790.1000248

  Abstract PDF

Relevant Topics